Authors: In Gyu Hwang Jung Hun Kang Sung Yong Oh Suee Lee SungHyun Kim KiHoon Song Choonhee Son Min Jae Park Myung Hee Kang Hoon Gu Kim Jeeyun Lee Young Suk Park Jong Mu Sun Hyun Jung Kim Chan Kyu Kim Seong Yoon Yi JoungSoon Jang Keunchil Park HyoJin Kim
Publish Date: 2015/06/04
Volume: 24, Issue: 1, Pages: 301-309
Abstract
The efficacy of erlotinib the epidermal growth factor receptor EGFR tyrosine kinase inhibitor has been demonstrated in patients with nonsmall cell lung cancer NSCLC and pancreatic cancer PC In the present study we evaluated the effect of epidermal growth factor EGF ointment on erlotinibrelated skin effects ERSEsThis was an openlabel noncomparative multicenter phase II trial The patients included those diagnosed with NSCLC or PC who were treated with erlotinib The effectiveness of the ointment was defined as follows 1 grade 2 3 or 4 ERSEs downgraded to ≤grade 1 or 2 grade 3 or 4 ERSEs downgraded to grade 2 and persisted for at least 2 weeksFiftytwo patients from seven institutes in Korea were enrolled with informed consent The final assessment included 46 patients 30 males 16 females According to the definition of effectiveness the EGF ointment was effective in 36 692 intention to treat patients There were no statistically significant differences in the effectiveness of the EGF ointment by gender p = 0465 age p = 0547 tumor type p = 0085 erlotinib dosage p = 0117 and number of prior chemotherapy sessions p = 0547 The grading for the average National Cancer Institute’s Common Terminology Criteria for Adverse Events NCICTCAE rating of rash/acne and itching improved from 202 ± 083 to 113 ± 089 and 152 ± 084 to 067 ± 090 respectively p 0001 The most common reason for discontinuing the study was progression of cancer 37
Keywords: